Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Alvotech's Denosumab Biosimilar Just Got EU Green Light—Here's Why It Matters
Alvotech (ALVO) landed European Commission approval for AVT03, a biosimilar knockoff of Amgen’s Prolia and Xgeva. Both originals contain denosumab, a widely-used drug for osteoporosis and bone-related cancer complications.
The play? Europe’s denosumab market is worth roughly $1.2 billion annually. A cheaper biosimilar could grab serious market share.
What got approved:
Distribution handled by STADA and Dr. Reddy’s across Europe.
The bigger picture: AVT03 already has Japan approval (September 2025) and FDA accepted the US filing in March 2025. The combo—EU + Japan + pending US—positions Alvotech as a serious player in biosimilar manufacturing.
Alvotech’s CEO pitched it as proof of their “end-to-end biosimilar platform.” They’ve already got approved biosimilars to Humira and Stelara in the pipeline.
Stock moves: ALVO closed Friday at $5.14 (up 1.58%), trading in a $4.70-$13.70 range over the past year. Approval catalysts like this typically move biotech stocks, though execution on commercialization is the real test.